Revision History

Manufacturers of mifepristone filed an emergency appeal to the U.S. Supreme Court on May 2, 2026, after the 5th Circuit Court of Appeals reinstated a nationwide in-person dispensing requirement, blocking mail and telehealth access to the drug used in roughly 65% of U.S. abortions. The case, Louisiana v. FDA, raises fundamental questions about state standing to challenge federal drug regulation, the reach of the 19th-century Comstock Act, and whether courts can override the FDA's scientific judgments — with implications that extend far beyond abortion to the stability of the entire pharmaceutical regulatory framework.